Patent · US Active

Method of treating asthma or reducing inflammatory cell lung inflammation by administering toll-like receptor 3 antibodies

US9238693B2 · kind B2 · utility

3Cited by

2References

9Claims

0Family size

Assignee

JANSSEN BIOTECH, INC. · US

Inventors

Mark Cunningham · Kennett Square, US
Yiqing Feng · Chesterfield, US
Katharine Heeringa · Spring House, US
Jinquan Luo · Malvern, US
Robert Rauchenberger · Martinsried, DE
Mark Rutz · Martinsried, DE
Lani San Mateo · Radnor, US
Robert Sarisky · Lansdale, US
Raymond Sweet · Via Enrico Fermi, US
Fang Teng · Radnor, US
Alexey Teplyakov · Spring House, US
Sheng-Jiun Wu · Broomall, US

Key dates

Filing date	Mar 13, 2013
Grant date	Jan 19, 2016
Priority date	—
Expiry date	Mar 13, 2033

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC12N2310/17
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

Toll Like Receptor 3 (TLR3) antibody antagonists, polynucleotides encoding TLR3 antibody antagonists or fragments thereof, and methods of making and using the foregoing are disclosed.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.